Skip to content
Search

Latest Stories

Pankaj Tripathi to star alongside Akshay Kumar in Oh My God 2?

Pankaj Tripathi to star alongside Akshay Kumar in Oh My God 2?

Akshay Kumar and Paresh Rawal starrer Oh My God released in 2012. The film was a super hit at the box office and even critics had praised it.

A few months ago, there were reports that a sequel to the film is on the cards, and now, according to a report in Pinkvilla, Pankaj Tripathi has been roped in to star alongside Akshay in Oh My God 2.


A source told the portal, “Oh My God 2 will feature Pankaj Tripathi as the lead character alongside Akshay Kumar, who gets back to play his role from the first part. The discussions have been going on for quite some time with Pankaj and everything is now locked.”

Reportedly, the shooting of the film will start in September this year. The source said, “The pre-production work has begun with a team working in isolation to explore the probable locations of shoot, and also deciding on designing the sets in the city. The film will be wrapped up in one go by the month of October.”

It is said that before starting Oh My God 2, Akshay will wrap up the shooting of Raksha Bandhan, will shoot for a major chunk of Ram Setu and one more movie.

Well, Tripathi and Kumar have worked together in Bachchan Pandey. The movie is yet to hit the big screens.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less